Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacological Studies of SSS11 in Patients With Gout and Hyperuricemia After Multiple Administrations, Dose Escalation, Randomized Double-blind, Placebo-controlled Trials
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Pegadricase (Primary)
- Indications Gout
- Focus Adverse reactions
Most Recent Events
- 28 May 2025 Planned End Date changed from 8 Aug 2025 to 8 Aug 2027.
- 28 May 2025 Planned primary completion date changed from 20 Apr 2025 to 20 Dec 2026.
- 11 Oct 2024 New trial record